Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganitumab + Endocrine Therapy in HR+ Breast Cancer
NCT00626106Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Mar 2008
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of ganitumab in breast cancer, sponsored by ImmunityBio, Inc.. Started Mar 2008; status: completed.
02
Drugs
ganitumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00626106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626106.